GHK-Cu Dosage in the Research Literature

GHK-Cu dosage, as it appears in the studies

GHK-Cu dosage in the research literature spans seven orders of magnitude because the models differ so widely, and none of it is a human usage instruction. The lowest figures are in vitro: fibroblast collagen synthesis is driven at 10^-12 to 10^-9 M, with onset around 10^-12 to 10^-11 M and a peak near 10^-9 M ^[1]. Topical cosmetic and clinical formulations run roughly 0.05% to 2% (w/w) in creams, serums and gels ^[13].

Rodent systemic studies sit in between. Pulmonary fibrosis used GHK at 2.6, 26 and 260 ug/mL/day intraperitoneally on alternate days ^[8]; DSS-colitis used GHK-Cu at 20 mg/kg by oral gavage ^[14]; behavioral studies used roughly 0.5 ug/kg to 0.5 mg/kg IP ^[10][11]; and the human hair trial used the ALAVAX 5-ALA + GHK topical at 50-100 mg/mL ^[4]. These are reported here so the literature is legible by species and route — not as a recommendation for any use.

Routes studied and the half-life question

GHK-Cu has been studied across an unusually wide route set: topical (cream, serum, liposome, nano-lipid carrier, ionic-liquid microemulsion, wound dressing and nanofiber), intraperitoneal, intranasal, oral gavage, intravenous/subcutaneous, and intradermal microneedle delivery ^[13]. The topical route is the one with regulatory standing and the most human data, and the routes diverge sharply in what they imply for exposure.

No rigorous human pharmacokinetic half-life has been published. The free tripeptide (340.38 Da) is rapidly cleared by plasma peptidases — a rat study documented rapid metabolism of GHK to the dipeptide HK after intravenous dosing — and secondary literature cites a short systemic elimination half-life on the order of 1-2 hours, with the copper-chelated complex more stable than free GHK ^[6]. That rapid systemic clearance is one reason the injectable-route claims are hard to substantiate: a molecule cleared in hours behaves very differently from a dermal depot.

Topically, the story is the opposite. Application forms a dermal copper depot, with about 97 ug/cm^2 retained over 48 hours after 136.2 ug/cm^2 permeated, giving prolonged local availability rather than a quick systemic pulse ^[5]. The practical reading is that topical and systemic GHK-Cu are almost two different pharmacological problems, and the topical one is the only route with both regulatory standing and human exposure data.

Stability: keeping the copper complex intact

The GHK-Cu complex is defined by its copper, and the stability data explains both its safety framing and its formulation rules. The complex carries a very high copper stability constant (log K ~16.44), far higher than free GHK, which limits pro-oxidant free-copper release ^[7]. It is most stable near pH 5-6.5 at a 1:1 copper:peptide ratio; the blue-violet color of a reconstituted solution is the expected Cu(II) absorption and indicates an intact complex, while brown or green shifts indicate oxidation or precipitation ^[6].

What breaks it is reducing chemistry. Strong reducing agents — ascorbic acid (vitamin C) below about pH 3.5 in particular — reduce Cu(II) and break the complex, and AHAs/BHAs and other low-pH actives can destabilize it or compete for the copper ^[13]. The practical research note is consistent across the formulation literature: keep the complex near neutral-to-mildly-acidic pH and away from strong reducers if the copper coordination is to survive ^[6][13].

Formulation strategies for a hard-to-deliver peptide

The dosing problem GHK-Cu cannot escape is that native delivery is poor. Free GHK is highly hydrophilic, with a clogP of -2.24 that resists passage through the stratum corneum, so most of the formulation literature is an effort to raise that number ^[13]. Palmitoylation produces Pal-GHK with a clogP near 1.14, a large lipophilicity shift that improves membrane partitioning ^[13].

Mechanical and carrier strategies do the same job differently. Liposomal encapsulation, nano-lipid carriers and ionic-liquid microemulsions package the peptide for better skin transit, while microneedle pretreatment bypasses the barrier physically — one study reported roughly 134 nmol of GHK permeating treated skin versus none through intact skin ^[13]. Hair studies have used intradermal microneedle and tattoo-machine delivery to place the peptide in the dermis directly ^[13]. The 2025 review frames all of these as promising but early-stage rather than established protocols ^[13]. The relevant point for dose interpretation is that the delivered dose and the applied dose can differ by orders of magnitude depending on the vehicle.

The human-data ceiling

What the research-dose picture cannot supply is a human systemic protocol, and the literature is explicit about that gap. Human evidence is predominantly topical and dermatologic: small placebo-controlled facial cream and serum trials (n roughly 20-71) reporting improved skin density, firmness, fine lines and wrinkle depth, plus the single 6-month hair-loss trial of an ALAVAX 5-ALA + GHK combination at 50-100 mg/mL ^[3][4][13]. There are no completed Phase 2/3 trials for systemic or injectable GHK-Cu; one topical wound-healing trial (CuHeal, NCT07437586) has been registered ^[6].

Injectable and systemic dosing protocols that circulate in community contexts have no peer-reviewed human pharmacokinetic basis — no validated half-life, Cmax, bioavailability or tissue-distribution data exist for those routes ^[6]. That is why every figure on this page is presented as a study parameter for a specific species and model, never as a usage instruction. The honest dosing statement for systemic GHK-Cu in humans is that one has not been established.